Core Insights - Haishun New Materials is a leading enterprise in the high-barrier packaging materials sector directly in contact with pharmaceuticals, established in 2005 and listed on the Shenzhen Stock Exchange in 2016 [1] Group 1: Business Performance - In Q3 2025, Haishun New Materials achieved a revenue of 823 million yuan, ranking first among six companies in the industry, with the second-ranked Tianyuan Co. generating 767 million yuan [2] - The revenue from new pharmaceutical packaging materials was 495 million yuan, accounting for 89.58% of total revenue, while other business revenue was 57.5 million yuan, making up 10.42% [2] - The net profit for the same period was 54.42 million yuan, placing the company second in the industry, with the first being Jinghua Laser at 73.13 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the asset-liability ratio for Haishun New Materials was 38.56%, higher than the previous year's 34.82% and above the industry average of 37.97% [3] - The gross profit margin was 22.93%, down from 29.69% year-on-year but still above the industry average of 14.09% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 12.81% to 13,500, while the average number of circulating A-shares held per account increased by 14.69% to 9,274.86 [5] - The top ten circulating shareholders included a new entrant, the Medical Device ETF (159883), holding 717,800 shares [5] Group 4: Executive Compensation - The chairman and general manager, Lin Wuhui, received a salary of 912,300 yuan in 2024, a slight increase from 912,000 yuan in 2023 [4]

Core Viewpoint - Haishun New Materials (300501) reported a significant increase in aluminum-plastic film sales, with a year-on-year growth exceeding 50% in the first three quarters of 2025, focusing on high-end medical and electronic film materials [1][2] Business Progress - The company highlighted that its aluminum-plastic film products are primarily used in the 3C soft-pack battery sector, with sales growth driven by their barrier, moisture-proof, and chemical resistance properties [1] - Strategies to enhance product competitiveness, expand sales channels, strengthen brand promotion, and improve customer service are being implemented to address market competition [1] - Plans to expand into the power battery and energy storage sectors are in place, aligning with the development of next-generation technologies like solid-state batteries [1] R&D Investment - R&D expenses increased year-on-year in the third quarter, focusing on high-end medical and electronic film materials, with some new products already certified by customers and entering the industrialization phase [2] Market and Shareholder Relations - The management acknowledged concerns regarding the long-term underperformance of the stock price, attributing it to multiple factors including market conditions and company performance [2] - Measures such as share buybacks, cash dividends, and employee stock ownership plans are being utilized to enhance market confidence [2] - Clarification was provided regarding the previously announced 180 million yuan as a bank approval credit limit, not actual funds received, emphasizing that buyback operations aim to protect company value and shareholder interests [2] Financial and Strategic Details - The company is focusing on the new consumption and renewable energy markets, achieving positive growth in sales revenue from consumer film products and aluminum-plastic films in the renewable energy sector [2] - The strategy includes advancing existing product processes and industrializing new products to diversify and address market challenges [2]

Core Insights - The company is increasing its R&D investment, focusing on high-end medical membrane materials and electronic membrane materials [1] - Some new products have already passed customer certification and entered the industrialization stage, which will provide new growth momentum for the company's future development [1] Summary by Categories - **R&D Investment** - The company is committed to enhancing its research and development efforts [1] - **Product Development** - New products in high-end medical and electronic membrane materials have received customer certification [1] - These products are now in the industrialization phase [1] - **Future Growth** - The advancements in product development are expected to drive future growth for the company [1]

Core Viewpoint - The company has reported significant growth in its aluminum-plastic film business, with a sales scale increase of over 50% year-on-year for the first three quarters of 2025, and aims to continue expanding sales to create greater value for shareholders [1] Company Summary - The aluminum-plastic film business has achieved a certain sales scale [1] - The company is committed to further expanding its sales scale in the future [1] - The focus on shareholder value creation is emphasized [1]

Group 1: Company Performance and Market Position - The company's aluminum-plastic film business has achieved a sales scale with a year-on-year growth of over 50% in the first three quarters of 2025 [8] - The company acknowledges that its stock price has been affected by various factors, including market environment, industry competition, and company performance [3][5] - The management team is committed to improving operational efficiency and decision-making quality to enhance long-term development [3][5] Group 2: Research and Development - R&D expenses have increased year-on-year, focusing on high-end medical film materials and electronic film materials, with some products entering the industrialization stage [4] - The company emphasizes the importance of R&D investment for new product development and existing product process iteration [4] Group 3: Sales and Marketing Strategies - The company is actively expanding sales channels and enhancing brand exposure through participation in trade shows [3][6] - Strategies to cope with market competition include improving product competitiveness, expanding new sales channels, and enhancing customer service [6] Group 4: Financial Management and Shareholder Relations - The company has a bank loan approval limit of 180 million, but the actual long-term borrowings reported are only 60 million, raising questions about the remaining 120 million [14] - The management expresses confidence in the company's future performance and is focused on optimizing internal management and resource allocation to improve market value [11][13] Group 5: Future Outlook - The company is closely monitoring industry trends, particularly in the solid-state battery sector, and aims to leverage its technical expertise in packaging materials [7] - The management is committed to enhancing communication with investors and ensuring transparency regarding company operations and strategies [9][11]

Core Points - The company announced the convening of the 42nd meeting of the 5th Board of Directors on October 28, 2025, to discuss the election of the 6th Board of Directors [1] - The company has nominated Huang Qin, Lin Xin, and Ni Hailong as candidates for non-independent directors of the 6th Board [1] - The company has also nominated Guo Xun, Ma Shihong, and Wang Linlin as candidates for independent directors of the 6th Board, all of whom have obtained the necessary qualifications or training certificates recognized by the Shenzhen Stock Exchange [1] - Wang Linlin is noted to be a professional in accounting [1]

Core Insights - Haishun New Materials (300501.SZ) reported a revenue of 823 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 0.42% [1] - The net profit attributable to shareholders was 48.67 million yuan, down 38.96% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 20.86 million yuan, a significant decline of 71.84% year-on-year [1] - Basic earnings per share stood at 0.26 yuan [1]

Core Insights - The company reported a revenue of 823 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 0.42% [1] - The net profit attributable to shareholders was 48.67 million yuan, showing a significant year-on-year decline of 38.96% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 20.86 million yuan, which is a substantial decrease of 71.84% year-on-year [1] - The basic earnings per share stood at 0.26 yuan [1]

关联交易管理制度 上海海顺新型药用包装材料股份有限公司 关联交易管理制度 第一章 总则 第一条 为进一步规范上海海顺新型药用包装材料股份有限公司（以下简称 "公司"）关联交易管理，明确关联交易决策程序和管理职责与分工，维护公司、 公司股东和债权人的合法利益，特别是中小投资者的合法利益，保证公司与关联 方之间订立的关联交易合同符合公平、公正、公开的原则，根据《中华人民共和 国公司法》、《中华人民共和国证券法》、《上市公司治理准则》、《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第7号— —交易与关联交易》等有关法律、法规、规范性文件及《上海海顺新型药用包装 材料股份有限公司章程》的相关规定，特制订本制度。 第二条 公司处理关联交易时，应遵循以下原则： （一）尽量避免或减少与关联人之间的关联交易； （二）确定关联交易价格时，应遵循"公平、公正、公开、等价有偿"的原 则，原则上不偏离市场独立第三方的标准，对于难以比较市场价格或定价受到限 制的关联交易的，应以成本加合理利润的标准来确定关联交易的价格； （三）公司董事会 ...

上海海顺新型药用包装材料股份有限公司 董事会战略发展委员会议事规则 董事会战略发展委员会议事规则 第一章 总 则 第一条 为适应上海海顺新型药用包装材料股份有限公司（以下简称"公司" 或"本公司"）战略发展需要，增强公司核心竞争力，确定公司发展规划，健全 投资决策程序，加强决策科学性，提高重大投资决策的效益和质量，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《上市公 司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上海海顺新型 药用包装材料股份有限公司章程》（以下简称"《公司章程》"）及其他有关法 律、法规和规范性文件的规定，公司特设立董事会战略发展委员会（以下简称"战 略发展委员会"），并制订本规则。 第二条 战略发展委员会是董事会按照《公司章程》设立的专门工作机构， 主要负责对公司中长期发展战略和重大战略投资决策进行研究并提出建议。 第三条 战略发展委员会所作决议，必须遵守《公司章程》、本议事规则及 其他有关法律、法规和规范性文件的规定。 第二章 人员组成 第四条 战略发展委员会成员由三名董 ...